Cell Line Authentication and Maintenance

Cells were obtained from ATCC and fingerprinted as in Barretina et al (Barretina et al., 2012 (link)). Cells were maintained in RPMI-1640 (NCI-H1299, HCC364, NCI-H1975, and HCC827; Corning, Corning, NY), McCoy’s 5A (CALU1; Gibco, Waltham, MA) or DMEM (MGH-065; Invitrogen, Carlsbad, CA) supplemented with 2 mM glutamine, 50 U/mL penicillin, 50 U/mL of streptomycin (Gibco), and 10% fetal bovine serum (Sigma, St. Louis, MO), and incubated at 37°C in 5% CO₂. MGH-065 cells were derived as previously described (Crystal et al., 2014 (link)). Cell lines were tested for mycoplasma prior to screening. Trametinib, vemurafenib, erlotinib, and afatinib, were purchased from Selleck Chemicals (Houston, TX). LDK-378 and Crizotinib were synthesized by the Novartis Global Discovery Chemistry Department.